Abstract:The Philadelphia chromosome (Ph) translocation, which leads to creation of a fusion gene product BCR-ABL, is found in chronic myelogenous leukemia (CML) and 20% of adult and 2-5% pediatric acute B-lymphoblastic leukemia (B-ALL). The selective ABL tyrosine kinase inhibitor (TKI) has been shown a remarkable clinical activity in patients with CML. The ABL TKI has also improved the clinical outcome of Ph+ B-ALL dramatically in combination with standard chemotherapy, but the morbidity and mortality of this disease remain high. The existence of ABL inhibitor-resistant leukemia cells in these patients indicates the presence of additional oncogenic pathways in Ph+ B-ALL. Discovery of a new therapeutic strategy to eradicate Ph+ B-ALL cells is, therefore, urgently needed. By using a chemical genetics approach, we identified a novel small molecule, AR4-13, which shows robust ABL kinase inhibition and potent pharmaceutical efficacy in Ph+ leukemias among 1094 cell lines from the Cancer Cell Line Encyclopedia (CCLE) project. Interestingly, AR4-13 possesses preferable potency than Dasatinib, a potent dual SRC/ABL TKI approved to treat CML and Ph+ B-ALL, to kill Ph+ B-ALL cells, but not do so in CML cells, both in vitro and in vivo. In particular, AR4-13 inhibits S6 and p38 phosphorylation much more potently than that of Dasatinib. Furthermore, kinome profiling data indicate that AR4-13 also inhibits Mitogen-activated protein kinase (MAPK) kinase kinase kinases (MAP4Ks), which belong to a kinase family that controls the MAPK signaling in lymphoid cells. Consistently, RNAi-based synthetic lethal screen with TKIs show that suppression of MAP4Ks could significantly enhance the sensitivity to ABL TKIs in Ph+ B-ALL cells, implying that MAP4K family kinases function as a parallel pathway to BCR-ABL signaling and confer ABL TKI resistance in Ph+ B-ALL. Our findings indicate that simultaneous targeting both the ABL and MAP4K signaling pathways might serve as a promising TKI therapeutic strategy for Ph+ B-ALL. Citation Format: Ruibao Ren, Xinhua Xiao, Jianming Zhang, Bo Jiao. Overriding drug resistance in Philadelphia chromosome-positive acute B lymphoblastic leukemia by targeting both BCR-ABL and MAP4K signaling pathways [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 398.

PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia

Abstract 3915: PBA2, a dual BCR-ABL and GSK3βkinases inhibitor, represses a wide array of Imatinib resistant cell lines in chronic myeloid leukemia

The Novel Anticancer Agent JNJ-26854165 is Active in Chronic Myeloid Leukemic Cells with Unmutated BCR/ABL and T315I Mutant BCR/ABL Through Promoting Proteosomal Degradation of BCR/ABL Proteins

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy.

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia

Potential role of Wnt/β-catenin signaling in blastic transformation of chronic myeloid leukemia: cross talk between β-catenin and BCR-ABL

Effects of Inactivating Ras-Converting Enzyme or Isoprenylcysteine Carboxyl Methyltransferase in the Pathogenesis of Chronic Myelogenous Leukemia

E3 Ligase C-Cbl Mediates Ubiquitination-Proteasomal Degradation Of Bcr-Abl And Therapeutic Effects Against Bcr-Abl Leukemia

Targeting protein tyrosine phosphatase non-receptor type 2 with a novel inhibitor for AML therapy

Discovery of a Candidate Containing an (S)-3,3-difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1h-inden Scaffold As a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.

Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity

Abstract 398: Overriding Drug Resistance in Philadelphia Chromosome-Positive Acute B Lymphoblastic Leukemia by Targeting Both BCR-ABL and MAP4K Signaling Pathways

Allosteric inhibitors of Bcr-abl–dependent cell proliferation

Discovery and Characterization of a Novel Potent Type II Native and Mutant BCR-ABL Inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

Proteasome Inhibition Causes Regression of Leukemia and Abrogates Bcr-Abl-Induced Evasion of Apoptosis in Part Through Regulation of Forkhead Tumor Suppressors

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)

Bcr-Abl drives the formation of Hsp70/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells

RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core‐binding factor‐acute myeloid leukaemia

Discovery and Characterization of a Novel Highly Potent and Selective Type II Native and Drug-Resistant V299L Mutant BCR-ABL Inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)